title: A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS.
abstract: This work evaluated possible advantages of gonadotrophin-releasing hormone (GnRH) antagonist administration as an alternative to coasting in prevention of severe ovarian hyperstimulation syndrome (OHSS) in women undergoing IVF/ intracytoplasmic sperm injection. A prospective randomized study comparing coasting (group A) (n = 96) and GnRH antagonist administration (group B) (n = 94) in patients at risk of OHSS was performed. The primary outcome measure was high quality embryos. The secondary outcome measures were days of intervention, number of oocytes, pregnancy rate, number of cryopreserved embryos and incidence of severe OHSS. There were significantly more high quality embryos (2.87 +/- 1.2 versus 2.21 +/- 1.1; P < 0.0001), and more oocytes (16.5 +/- 7.6 versus 14.06 +/- 5.2; P = 0.02), in group B as compared with group A. There were more days of coasting as compared with days of antagonist administration (2.82 +/- 0.97 versus 1.74 +/- 0.91; P < 0.0001). In conclusion, GnRH antagonist was superior to coasting in producing significantly more high quality embryos and more oocytes as well as reducing the time until HCG administration. There was no significant difference in pregnancy rate between the two groups. No OHSS developed in either group.
authors.affiliation: The Egyptian IVF-ET Centre, 3 St 161, Hadaek El Maadi, Maadi, Cairo 1143, Egypt. ghar@link.net
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Aboulghar
authors.forename: Ragaa T
authors.initials: RT
authors.lastname: Mansour
authors.forename: Yahia M
authors.initials: YM
authors.lastname: Amin
authors.forename: Hesham G
authors.initials: HG
authors.lastname: Al-Inany
authors.forename: Mona M
authors.initials: MM
authors.lastname: Aboulghar
authors.forename: Gamal I
authors.initials: GI
authors.lastname: Serour
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy
chemical_list: D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix